Steve St. Onge | SVP - Corporate Development
Clarametyx Biosciences

Steve St. Onge, PharmD, MBA is a biotechnology executive with over 15 years of experience in corporate development, M&A, licensing, medical affairs and clinical practice.  Prior to joining Clarametyx in 2024, Dr. St. Onge led corporate development, licensing and corporate communications at Paratek Pharmaceuticals, playing a pivotal role in the achievement of multiple corporate milestones, including the approval and successful launch of NUZYRA® (omadacycline) and the company’s $462 million take-private transaction by Gurnet Point Capital and Novo Holdings in 2023.  Earlier in his career, Dr. St. Onge held roles of increasing responsibility in medical affairs and clinical research at Paratek, Tardis, and The Medicines Company.  Dr. St. Onge began his career as a critical care pharmacy specialist and maintains active faculty appointments in the department of anesthesia at Advent Health University and the University of Scranton.  Dr. St. Onge earned a Doctor of Pharmacy degree from the Albany College of Pharmacy and MBA from Endicott College.